Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00177138 · ClinicalTrials.gov registry record · Phase 4
Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation
A Phase 4 study, sponsored by University of Minnesota.
- Terminated
- Registry status
- Phase 4
- Development phase
- 9
- Enrollment target
NCT00177138: Clinical Trial Phase 4 study, sponsored by University of Minnesota.
NCT00177138 is a Phase 4 study that was terminated before completion, run by University of Minnesota. The registered enrollment target is 9 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00177138, a Phase 4 study, was terminated before completion, sponsored by University of Minnesota.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 9 participants
- Enrollment target
Study Summary
This is a single center, prospective, open-label, randomized trial at the University of Minnesota Medical Center,Fairview. Primary objectives are to determine if rejection episodes and loss rates, graft survival, level of renal graft function, and patient survival rates with a Campath/MMF-based (Group 1) immunosuppressive protocol are lower than, or equal to, our protocol using thymoglobulin, tacrolimus, and MMF (Group 2). This study will investigate the first protocol that is both steroid-free and calcineurin inhibitor-free in pancreas after kidney transplant recipients.
Interventions
- DRUG Alemtuzumab
- DRUG Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-11 |
| Phase | Phase 4 |
Why NCT00177138 stopped before completion
NCT00177138 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Alemtuzumab is the first listed.
NCT00177138 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00177138 about?
NCT00177138 is a clinical study titled "Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation". This is a single center, prospective, open-label, randomized trial at the University of Minnesota Medical Center,Fairview. Primary objectives are to determine if rejection episodes and loss rates, graft survival, level of renal graft function, and patient survival rates with a Campath/MMF-based (Gr...
What is the current status of trial NCT00177138?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 9 participants. The study started on 2004-07. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00177138?
The interventions under investigation include: Alemtuzumab (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00177138?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00177138's enrollment target sits among peer trials
9 1968th of 2000 higher than 29 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia